Wide Ranks

INM

InMed Pharmaceuticals Inc.

4.30

Top Statistics
Market Cap 3 M Forward PE -0.6880 Revenue Growth -44.50 %
Current Ratio 4.41 Trailing PE 0.0187 Earnings Growth 0.00 %
Profit Margins -166.94 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -6.50 Enterprise / Revenue 11.19 Price To Sales Trailing12 Months 0.6716
Profitability
Profit Margins -166.94 % Operating Margins -156.58 %
Balance Sheet
Total Cash 6 M Total Cash Per Share 0.4960 Total Debt 962662
Total Debt To Equity 10.46 Current Ratio 4.41 Book Value Per Share 1.03
All Measures
Short Ratio 12.00 % Message Board Id finmb_9199217 Fax 778 945 6800
Shares Short Prior Month 4658 Return On Equity -0.7208 City Vancouver
Uuid 54d72c02-33c2-35ea-9933-95bec823badf Previous Close 4.53 First Trade Date Epoch Utc 1 B
Book Value 1.03 Beta 0.7110 Total Debt 962662
Volume 19621 Price To Book 4.17 Last Split Date 1 B
Fifty Two Week Low 2.42 Total Cash Per Share 0.4960 Total Revenue 4 M
Shares Short Previous Month Date 1 B Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -156.58 % Net Income To Common -7675550 Short Percent Of Float 0.0087
Implied Shares Outstanding 17 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 57890 Average Volume10days 57890 Total Cash 6 M
Next Fiscal Year End 1 B Revenue Per Share 0.6030 Ebitda Margins -172.15 %
Trailing PE 0.0187 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 4.53 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 4.84 Open 4.52 Free Cashflow -4022098
State BC Dividend Yield 0.00 % Return On Assets -0.3921
Time Zone Short Name EST Trailing Eps 230.40 Day Low 4.20
Address1 885 West Georgia Street Shares Outstanding 718078 Price Hint 4
Target High Price 0.0000 Website https://www.inmedpharma.com 52 Week Change -0.5114
Average Volume 48488 Forward Eps -6.25 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 353.40 % Last Split Factor 1:20
Regular Market Day High 4.75 Is_sp_500 False Profit Margins -166.94 %
Debt To Equity 10.46 Fifty Two Week High 15.70 Day High 4.75
Shares Short 5776 Regular Market Open 4.52 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 11.19 Revenue Growth -44.50 %
Shares Percent Shares Out 0.0087 Operating Cashflow -6985832 Currency USD
Time Zone Full Name America/New_York Market Cap 3 M Is_nasdaq_100 False
Zip V6C 3E8 Quote Type EQUITY Industry Biotechnology
Long Name InMed Pharmaceuticals Inc. Regular Market Day Low 4.20 Current Price 4.30
Address2 Suite 1445 Enterprise To Ebitda -6.50 Financial Currency USD
Current Ratio 4.41 Gross Margins 23.95 % Industry Disp Biotechnology
Country Canada Float Shares 13 M Two Hundred Day Average 5.61
Enterprise Value 51 M Price To Sales Trailing12 Months 0.6716 Forward PE -0.6880
Regular Market Volume 19621 Ebitda -7914830 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.

It operates through two segments: InMed Pharma and BayMedica Commercial.

The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products.

The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.

Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs.

The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.

It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases.

In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin.

The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.

InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.